Xeris Biopharma Holdings (XERS) Lifts Outlook As Valuation Questions Follow Its Sharp Rally

Simply Wall St · 2d ago

Xeris Biopharma Holdings (XERS) came into focus after raising its full year 2026 revenue outlook to a range of US$395 million to US$405 million, alongside releasing new third quarter and nine month financial figures.

The guidance raise came on a stock that had already been on a steep run, with a 30-day share price return of 70.52%, a 90-day gain of 93.72%, and a year-to-date share price return of 126.67% at a latest share price of US$16.66.

Scan how Xeris Biopharma Holdings fits into a wider set of healthcare opportunities by comparing it against our hand picked 36 healthcare AI stocks.

Xeris Biopharma Holdings now trades only slightly below the analyst price target, yet still at a steep discount to some intrinsic value estimates. Is the recent surge already pricing in most of that gap?

Most Popular Narrative: 36% Overvalued

Xeris Biopharma Holdings closed at $16.66 against an analyst consensus fair value of $12.29 from the analyst consensus Narrative on Simply Wall St. This points to a premium price that investors need to weigh against the growth story embedded in the forecasts.

Persistent high gross margins, alongside scaling sales of Gvoke, Recorlev, and Keveyis, set the stage for operational leverage and sustainable EBITDA and net margin improvements as revenue expands and expense ratios decline over time.

See why 9 investors see Xeris Biopharma Holdings as 36% overvalued.

Result: Fair Value of $12.29 (OVERVALUED)

Still, the whole Xeris Biopharma Holdings story leans heavily on just a few therapies, and any setback for XP-8121 in Phase 3 could quickly challenge that upbeat narrative.

Find out about the key risks to this Xeris Biopharma Holdings narrative.

Another View: Xeris Biopharma Holdings Through A Cash Flow Lens

Analysts on Simply Wall St see Xeris Biopharma Holdings as overvalued at $16.66 versus a fair value of $12.29, yet the SWS DCF model points in the opposite direction, with an estimated future cash flow value of $30.07 per share and an implied 44.6% discount. Which story do you trust more: the multiple based target or the cash flow math?

Look into how the SWS DCF model arrives at its fair value.

XERS Discounted Cash Flow as at Nov 2026
XERS Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Xeris Biopharma Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals in the Xeris Biopharma Holdings story so far. If you want to move quickly and form your own take, review the balance of 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Xeris Biopharma Holdings?

If Xeris Biopharma Holdings sparked your interest, use that momentum. The quickest edge often comes from widening your watchlist before the crowd catches up.